The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 44.75
Bid: 44.00
Ask: 45.50
Change: -0.40 (-0.88%)
Spread: 1.50 (3.409%)
Open: 45.50
High: 45.10
Low: 45.10
Prev. Close: 45.50
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Avacta Announces GBP2 Million Subscription With Two Subscribers

Thu, 02nd Apr 2020 14:55

(Alliance News) - Avacta Group PLC on Thursday said it plans to raise GBP2 million through a 11.1 million share subscription priced at 18 pence per share with two subscribers.

Shares in Avacta were down 4.7% at 20.25 pence in London on Thursday.

The subscribers will be Clare Hughes, who is the wife of Zeus Capital co-founder Richard Hughes, and Boohoo.com co-founder Mahmud Kamani. Shareholder approval for the subscription is requirement and a general meeting notice will be sent out "shortly".

Avacta developed the Affimer platform, intended as an alternative to antibodies in diagnostics and treatment.

"The company intends to utilise the net proceeds of the subscription to continue to execute the strategy outlined last October. The company's key objectives are to enter the clinic with its first preCISION chemotherapy programme, to secure further significant drug development partnerships that help progress the company's technology platforms, and to continue to grow revenues and secure licensing partnerships for Affimer diagnostics reagents," said Avacta.

"Given the current economic climate the board have deemed it prudent to take on a small amount of additional equity capital at this time to ensure that it is in a strong position to exploit progress after the coronavirus pandemic is over," the firm added.

Having inked a collaboration and option agreement with ADC Therapeutics SA in late 2019, the firm has subsequently expanded the LG Chem Life Sciences Partnership and established a South Korean joint venture with Daewoong Pharmaceutical Co Ltd.

Avacta plans to post its results for the 17 months ended December 31 "later this quarter", having ended December with a GBP8.7 million cash balance.

At present, the firm does not foresee its revenue being "materially affected" by Covid-19 or to suffer "significant delays of more than a few weeks", though "is reliant on clinical trials proceeding in the UK by the end of the year".

"The small amount of additional capital raised through the subscription will help to ensure that the company can deliver on key milestones despite the Covid-19 pandemic," said Avacta.

By Anna Farley; annafarley@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
16 Mar 2022 13:02

Avacta offloads animal health unit in £2.3m deal

(Sharecast News) - Clinical-stage oncology drug company Avacta Group announced on Wednesday that Vimian Group has acquired its veterinary division, Avacta Animal Health, for consideration of up to £2.3m.

Read more
16 Mar 2022 11:38

Avacta sells veterinary division to Vimian for up to GBP2.3 million

(Alliance News) - Avacta Group PLC on Wednesday said it sold its veterinary division Avacta Animal Health to veterinary company Vimian Group AB.

Read more
3 Feb 2022 12:31

Avacta moves to next dose in first-in-human chemotherapy trial

(Sharecast News) - Clinical-stage oncology drug company Avacta announced on Thursday that the first-in-human phase 1 trial of 'AVA6000' pro-doxorubicin would advance to the next dose cohort, following a positive review of the safety data from the dosing of the first cohort.

Read more
3 Feb 2022 11:10

Avacta shares up 12% after chemotherapy drug advances to next stage

Avacta shares up 12% after chemotherapy drug advances to next stage

Read more
18 Jan 2022 14:36

Avacta Group selects second pro-drug candidate

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Tuesday that the next 'preCISION' drug candidate, 'AVA3996', had been selected for preclinical development, with a view to a first-in-human phase one clinical trial from the second half of 2023.

Read more
18 Jan 2022 13:52

Avacta selects potential tumour treatment for preclinical development

Avacta selects potential tumour treatment for preclinical development

Read more
18 Jan 2022 10:58

AIM WINNERS & LOSERS: Sanderson Design lifts outlook, Gattaca lowers

AIM WINNERS & LOSERS: Sanderson Design lifts outlook, Gattaca lowers

Read more
10 Jan 2022 12:16

LONDON MARKET MIDDAY: Stocks slip as investors brace for Fed testimony

LONDON MARKET MIDDAY: Stocks slip as investors brace for Fed testimony

Read more
10 Jan 2022 12:08

Abingdon Health plunges after Avacta stops selling Covid-19 test

Abingdon Health plunges after Avacta stops selling Covid-19 test

Read more
10 Jan 2022 11:29

AIM WINNERS & LOSERS: Avacta sinks as halts sales of Covid-19 tests

AIM WINNERS & LOSERS: Avacta sinks as halts sales of Covid-19 tests

Read more
10 Jan 2022 11:05

Shares plummet as Avacta pauses sale of lateral flow tests

(Sharecast News) - Avacta Group has suspended sales of its antigen lateral flow tests, causing the AIM-listed firm's share price to plummet.

Read more
10 Jan 2022 09:20

Avacta shares drop as Covid tests show reduced sensitivity to Omicron

Avacta shares drop as Covid tests show reduced sensitivity to Omicron

Read more
22 Dec 2021 12:21

LONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures

LONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures

Read more
22 Dec 2021 11:28

AIM WINNERS & LOSERS: BlueRock hit by Covid; D4T4 up on contract wins

AIM WINNERS & LOSERS: BlueRock hit by Covid; D4T4 up on contract wins

Read more
22 Dec 2021 10:31

Avacta shares up as flow tests receive CE mark for self-test use

Avacta shares up as flow tests receive CE mark for self-test use

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.